Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

10 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Cutaneous End Organ Assessments Week 38 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 38

- 15/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 32 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 32

- 12/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 28 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 28

- 12/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 28.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 24 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 24

- 12/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 20 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 20

- 12/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 20.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 16 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 16

- 12/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 12 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 12

- 10/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 8 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 8

- 09/07/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 8.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 4 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 4

- 11/06/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 4.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Day 1 Pre-Infusion

- 11/06/17 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial